JCO Global Oncology最新文献

{"title":"Impact of the COVID-19 Pandemic on Breast Cancer Patient Care: Results From a Tertiary Care Center in Lebanon.","authors":"Mariam Zahwe, Nader Zalaquett, Rima Kamel, Joodi Mourhli, Rami Abdul Baki, Ryan Osgueritchian, Hadi Hamdan, Karim Lakkis, Lilass Sinno, Salim G Habib, Walid El Hout, Tamam Tulimat, Chandrakanth Are, Hazem Assi, Mohamad Jawad Khalifeh, Umayya Musharrafieh, Ghina Ghazeeri, Ayman Harakeh, Eman Sbaity","doi":"10.1200/GO-24-00275","DOIUrl":"https://doi.org/10.1200/GO-24-00275","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to evaluate the impact of COVID-19 on breast cancer care in terms of the stage at presentation, treatment delays, and follow-up in a tertiary care center in Lebanon.</p><p><strong>Materials and methods: </strong>This retrospective study compared patients with breast cancer who presented to a tertiary care center in Lebanon before (September 2019-December 2019) and during (September 2020-December 2020) the COVID-19 pandemic. We extracted data from the electronic medical records of patients with breast cancer who had their initial presentation, were under treatment, or were on follow-up during our period of interest.</p><p><strong>Results: </strong>Of the 333 patients, 186 visited the hospital in the pre-COVID-19 period and 147 during the pandemic, showing almost a 12% reduction in the number of patients during the COVID-19 pandemic. In the pre-COVID period, more patients were presented for screening (52%); however, more symptomatic patients were presented during the pandemic (51.4%). Almost 54% had an advanced stage at presentation during the pandemic compared with 48% before the pandemic but with no statistical significance (<i>P</i> = .50). Significantly fewer patients came for chemotherapy in the COVID-19 period (38.1%) compared with the pre-COVID-19 period (52.2%). Fewer patients underwent surgery during the pandemic, although the difference was not statistically significant. Multivariate analysis showed that the COVID-19 pandemic was not associated with having an advanced stage at presentation (<i>P</i> = .24).</p><p><strong>Conclusion: </strong>The management of breast cancer was not substantially affected by the COVID-19 pandemic in a sample of Lebanese patients. However, 4 months might not be sufficient to draw a solid conclusion.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400275"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring Stigma in Pediatric Oncology: A Cross-Sectional Analysis of Three Global Sites.","authors":"Lara E Counts, Robin S Tanner, Yichen Chen, Meenakshi Devidas, Gia Ferrara, Inam Chitsike, Nester Chokwenda, Edith Matsikidze, Ana M Cáceres-Serrano, Lucia Fuentes, Thelma Velasquez Herrera, Hadeel Halalsheh, Nadine Fraihat, Nickhill Bhakta, Sima Jeha, Victor M Santana, Sara M Malone, Dylan E Graetz","doi":"10.1200/GO.24.00213","DOIUrl":"10.1200/GO.24.00213","url":null,"abstract":"<p><strong>Purpose: </strong>Stigma contributes to fear and shame, resulting in delays in care-seeking behavior among individuals with cancer. As a social construct, stigma is affected by language, religion, culture, and local norms. This study explored pediatric cancer stigma at the time of diagnosis across diverse settings through the adaptation of two stigma measures.</p><p><strong>Methods: </strong>This study was conducted with adolescents and caregivers of children with osteosarcoma and retinoblastoma at three centers in Jordan, Guatemala, and Zimbabwe. The Stigma-related Social Problems (SSP) and the eight-item Stigma Scale for Chronic Illness (SSCI-8) measures were translated into Arabic, Spanish, and Shona and contextually adapted for use with adolescents and caregiver proxies. Adapted measures were pilot-tested and iteratively revised.</p><p><strong>Results: </strong>Extensive adaptations were made to both measures to make them relevant to the local pediatric contexts. The final measures were used in nine patients and 28 caregivers. The exploratory analysis found that domain-specific and overall scale scores for both measures indicate a higher level of stigma than those found in previous studies (SSP: patient [51.23], caregiver [40.74]; SSCI-8: patient [50.41], caregiver [49.78]). Paired, patient-caregiver proxy responses were analyzed, with disagreement between the pairs for both scales.</p><p><strong>Conclusion: </strong>Adapted measures detected high levels of stigma among patients with pediatric cancer and their caregiver proxies and demonstrated a lack of concordance in the reports. This suggests the importance of studying stigma in this population and the need to ask patients about their stigma without using proxy measures. The required adaptations suggest a need for stigma measures developed specifically for pediatric cancer.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400213"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Radiation Therapist Education and Training: An International Survey.","authors":"","doi":"10.1200/GO-24-00618","DOIUrl":"https://doi.org/10.1200/GO-24-00618","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400618"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources.","authors":"Diana Del Cisne Pineda, Gabriel Berlingieri Polho, Yumi Ricucci Shinkado, Gustavo Alves Contado, Nathalia de Souza Crusoe, Vivian Naomi Horita, Joao Carlos Resende, Jamile Almeida Silva, Guilherme Fialho de Freitas, David Queiroz Muniz, Caio V Suartz, Leopoldo Alves Ribeiro-Filho, Paulo M Hoff, José Mauricio Mota","doi":"10.1200/GO-24-00464","DOIUrl":"10.1200/GO-24-00464","url":null,"abstract":"<p><strong>Purpose: </strong>Prior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more effective treatments.</p><p><strong>Methods: </strong>We retrospectively reviewed our institutional database to identify patients with mCRPC treated with cyclophosphamide. Prostate-specific antigen decrease ≥50% from baseline (PSA50) response was determined as the proportion of patients achieving a prostate-specific antigen (PSA) decline ≥50% from baseline. Radiographic responses and progression were evaluated by Prostate Cancer Working Group 3. Survival estimates used the Kaplan-Meier method, and correlations were made with Chi-square test for categorical variables.</p><p><strong>Results: </strong>From January 2011 to January 2023, 341 patients with mCRPC received oral cyclophosphamide at a tertiary cancer center in São Paulo, Brazil. The most common regimen (95%) was 100 mg once daily 21 days on, 7 days off. At prostate cancer diagnosis, the median age was 64.4 years (IQR, 59.4-70.8), 61.9% had metastatic de novo disease, and 55.5% had Gleason ≥8. The median number of previous treatment lines was three (IQR, 2-4). Any PSA decline was observed in 33.4%, and 13.2% had a PSA50 response. Median response duration was 2.1 months (IQR, 1.4-3.8). Ten patients (3%) were treated for ≥1 year. PSA50 response was associated with no prior docetaxel use and Eastern Cooperative Oncology Group performance status 0 or 1.</p><p><strong>Conclusion: </strong>Oral cyclophosphamide is a feasible treatment option for patients with mCRPC, particularly in a scenario of limited health care resources.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400464"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic Testing in Brazil: Navigating Challenges and Harnessing Opportunities for Global Health Impact.","authors":"Guilherme Harada, Tiago Biachi de Castria, Fabio Y Moraes","doi":"10.1200/GO-24-00545","DOIUrl":"https://doi.org/10.1200/GO-24-00545","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400545"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of <i>EGFR</i> Mutations in Patients With Resected Stage I to III Nonsquamous Non-Small Cell Lung Cancer: Results of India Cohort.","authors":"Ullas Batra, Kumar Prabhash, Vanita Noronha, Ramakant Deshpande, Sachin Khurana, Gull Mohammad Bhat, Rajesh Mistry, Vivek Agarwala, Sajjan Rajpurohit, Bhavesh Poladia, Mansi Sharma, Saquib Zaffar Banday","doi":"10.1200/GO-24-00353","DOIUrl":"10.1200/GO-24-00353","url":null,"abstract":"<p><strong>Purpose: </strong>The spectrum of <i>EGFR</i> is inadequately researched in patients with early-stage non-small cell lung cancer (NSCLC) in India. EARLY-epidermal growth factor receptor (EGFR) India (ClinicalTrials.gov identifier: NCT04742192), as part of a noninterventional, real-world global study, evaluated the prevalence of <i>EGFR</i> mutations in early-stage NSCLC in India.</p><p><strong>Methods: </strong>Prospective data from adult patients with surgically resected stage IA to IIIB (American Joint Committee on Cancer eighth edition) NSCLC between March 2021 and October 2022 were analyzed. In addition to descriptive statistics, Fisher's exact test with Monte Carlo was used to determine the association between <i>EGFR</i> mutations and clinicodemographic parameters.</p><p><strong>Results: </strong>Of 74 patients (median age, 57.0 [range, 33.0-77.0] years) enrolled from eight centers in India, 73.0% (54 of 74) were males, 56.1% (37 of 66) were nonsmokers, and 95.9% (71 of 74) had adenocarcinoma. The <i>EGFR</i> mutation prevalence was 26.0% (19 of 73), of which <i>Exon-19</i> deletions were the predominant subtype (13, 68.4%) followed by <i>Exon 21-L858R</i> (4, 21.1%), <i>Exon 20-T790M</i> (1, 5.3%), and compound (1, 5.3%) mutations. Nearly half (48.6%, 36 of 74) of the patients underwent only surgical resection. The remaining 51.4% (38 of 74) of the patients were prescribed neoadjuvant (n = 12; 16.2%) and adjuvant (n = 31; 41.9%) systemic therapies, and one patient (1.4%) received radiotherapy along with systemic therapy. In 60 patients with stage IB to IIIB NSCLC, systemic therapies, mainly platinum-based chemotherapy, were prescribed in 36 (60.0%). Only 8.1% (6 of 74) of the patients were prescribed EGFR-tyrosine kinase inhibitor (TKI), of which two received neoadjuvant and four were planned for adjuvant EGFR-TKI. Two (2.7%) patients were prescribed adjuvant immunotherapy. The univariate analysis showed higher odds of <i>EGFR</i> mutation for females (odds ratio, 3.96; <i>P</i> = .017).</p><p><strong>Conclusion: </strong>EARLY-EGFR India results showed the prevalence of <i>EGFR</i> mutation to be 26%. The study emphasized the pressing need for up-front biomarker testing at diagnosis to ensure optimal and timely personalized treatment.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400353"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing Landscape of Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma Treatment and Survival Trends in Thailand: A 13-Year Multicenter Retrospective Study of Patients.","authors":"Nuttapong Ngamphaiboon, Arunee Dechaphunkul, Chanida Vinayanuwattikun, Pongwut Danchaivijitr, Thanaporn Thamrongjirapat, Anussara Prayongrat, Tanadech Dechaphunkul, Rungarun Jiratrachu, Poompis Pattaranutaporn, Chuleeporn Jiarpinitnun, Jiraporn Setakornnukul","doi":"10.1200/GO-24-00285","DOIUrl":"10.1200/GO-24-00285","url":null,"abstract":"<p><strong>Purpose: </strong>The incidence and survival rates of head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC) vary globally, influenced by factors such as ethnicity, lifestyle, and health care systems.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients with HNSCC treated between 2008 and 2020 in four major Thai academic cancer centers, using a multidisciplinary multicenter database. The study focused on the evolution of patient characteristics, survival changes, and treatment landscape alterations over time.</p><p><strong>Results: </strong>Among 6,319 patients, the most common primary sites were nasopharynx (33%), oral cavity (23%), oropharynx (17%), larynx (15%), and hypopharynx (8%). An increase in human papillomavirus-related oropharyngeal carcinoma was noted, from 13% in 2008 to 42% in 2019-2020. The majority of patients presented with locally advanced (LA) stages (IVa/b: 50%, III: 26%). Chemoradiotherapy (54%) and surgery (24%) were the main treatments, with cisplatin (79%) being most commonly used in chemoradiation. Overall survival (OS) improved annually across all subsites, correlating with an increase in intensity-modulated radiotherapy (IMRT) use, from 25% in 2008 to 90% in 2019-2020. The median follow-up duration was 4.59 years, with a minimum of 2.75 years. Patients treated with IMRT had significantly longer OS compared with those treated with non-IMRT techniques, in both NPC and non-NPC HNSCC (<i>P</i> < .001).</p><p><strong>Conclusion: </strong>To our knowledge, this is the largest study in Thailand that demonstrates increasing survival outcomes in patients with HNSCC and NPC, despite commonly presenting with LA stages. The increasing use of IMRT may be contributing to improved survival outcomes in both patients with NPC and non-NPC HNSCC patients.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400285"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape of Multilocus Inherited Neoplasia Allele Syndrome in Mexican Population.","authors":"Dione Aguilar, María L Garza-Rodríguez, Diana C Pérez-Ibave, Carolina E Muñiz-Garza, Victor Treviño, Cynthia M Villarreal-Garza, Oscar Vidal-Gutiérrez, Carlos H Burciaga-Flores","doi":"10.1200/GO.24.00065","DOIUrl":"https://doi.org/10.1200/GO.24.00065","url":null,"abstract":"<p><strong>Purpose: </strong>Hereditary cancer syndromes (HCS) explain 5%-10% of all cancer cases. Patients with more than one germline pathogenic variant (GPV) result in a clinical syndrome known as multilocus inherited neoplasia allele syndrome (MINAS). In recent years, an increasing number of MINAS cases have been reported. This study aims to identify the prevalence of MINAS and determine the effect of two GPVs in HCS on patients from Northern Mexico.</p><p><strong>Methods: </strong>Patients (N = 2,282) were recruited from four public oncology centers and two private institutions with hereditary cancer detection programs in Nuevo León, México. A medical geneticist collected all the patient's clinical data and gave genetic counseling. Patients with MINAS were detected using multigene panels to detect GPVs; findings were classified according to American College of Medical Genetics and Genomics guidelines. The genetic data of patients with MINAS were evaluated by their frequency and combination.</p><p><strong>Results: </strong>We found 386 (16.9%) patients with one or more variants and 23 (5.9%) MINAS patients (all females). The most frequent diagnosis was breast cancer (BC) in 20 (86.95%) cases, whereas 16 (69.56%) had triple-negative BC. We found 13 patients with <i>BRCA1</i> GPVs (56.52%) as the most frequent, followed by <i>MUTYH</i> with five cases (21.73%). The combinations of <i>BRCA1/CHEK2</i>, <i>BRCA1/CDKN2A</i>, and <i>BRCA1/BRCA2</i> were the most frequent. We found no atypical presentation in the cohort.</p><p><strong>Conclusion: </strong>This is the first Mexican MINAS report and the largest Latin American cohort. We detected a higher prevalence of MINAS than other populations (5.9%). We found a tendency for additive phenotypical effect and, in some MINAS combinations, a modification in the age of diagnosis.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400065"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Next-Generation Sequencing of Cell-Free DNA to Detect <i>MYC</i>-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa.","authors":"Clara Chamba, Daisy Jennings, Rehema Shungu, Heavenlight Christopher, Emmanuel Josephat, Kieran Howard, Helene Dreau, Adam Burns, William Mawalla, Priscus Mapendo, Leah Mnango, Ismail Legason, Edrick Elias, Caroline Achola, Anthony Cutts, Emmanuel Balandya, Anna Schuh","doi":"10.1200/GO.24.00210","DOIUrl":"https://doi.org/10.1200/GO.24.00210","url":null,"abstract":"<p><strong>Purpose: </strong>Epstein-Barr virus (EBV)-positive Burkitt lymphoma (BL) affects children in sub-Saharan Africa, but diagnosis via tissue biopsy is challenging. We explored a liquid biopsy approach using targeted next-generation sequencing to detect the <i>MYC</i>-immunoglobulin (<i>MYC</i>-Ig) translocation and EBV DNA, assessing its potential for minimally invasive BL diagnosis.</p><p><strong>Materials and methods: </strong>The panel included targets for the characteristic <i>MYC</i>-Ig translocation, mutations in intron 1 of <i>MYC</i>, mutations in exon 2 of <i>MYC</i>, and three EBV genes: EBV-encoded RNA (EBER)1, EBER2, and EBV nuclear antigen 2. It was first tested in a small derivation cohort of four precharacterized BL-derived cell lines with known translocation status and eight precharacterized plasma samples with known EBV DNA status by quantitative polymerase chain reaction (qPCR). These different data modalities were combined to assess the accuracy of this approach in the diagnosis of BL in 20 patient plasma samples in Tanzania and Uganda.</p><p><strong>Results: </strong>The next-generation sequencing panel detected three of four <i>MYC</i>-Ig translocations in the BL-derived cell lines. EBV viral load by targeted sequencing correlated strongly with qPCR results (Spearman's rho = 0.94) in precharacterized plasma samples. Using the patient plasma samples, mutations in <i>MYC</i> intron 1 were associated with the presence of a <i>MYC</i> translocation with 25 or more mutations being predictive of a translocation with AUC, sensitivity, and specificity of 1. Overall, liquid biopsy parameters associated with a diagnosis of BL (<i>P</i> < .05) included cell-free DNA concentration, circulating tumor DNA concentration, <i>MYC</i> intron 1 mutations, <i>MYC</i>-Ig translocation, and autosome entropy. Integrating these parameters into a diagnostic model demonstrated excellent performance with an AUC of 0.95, sensitivity of 0.9, and specificity of 1.</p><p><strong>Conclusion: </strong>This analysis demonstrates the potential of liquid biopsy to improve BL diagnosis in settings with limited pathology resources. Validation of our approach in a larger data set is needed.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400210"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape of Global Pediatric Oncology Publications: A Cross-Sectional Analysis.","authors":"María Fernanda García Garza, Oscar Gutiérrez Treviño, Saman K Hashmi, Carlos Rodríguez-Galindo, Daniel C Moreira","doi":"10.1200/GO-24-00320","DOIUrl":"https://doi.org/10.1200/GO-24-00320","url":null,"abstract":"<p><strong>Purpose: </strong>The academic field of global pediatric oncology is expanding as cancer becomes increasingly recognized as a global health priority for children and adolescents. Here, we aimed to explore the representation of authors, the geographic distribution of research, and the research approaches being used in global pediatric oncology.</p><p><strong>Methods: </strong>Articles published in <i>JCO Global Oncology</i> (<i>JCO GO</i>) and <i>Pediatric Blood and Cancer</i> on the topic of global pediatric oncology were analyzed. For each article, data were collected on the study design, the research location, and the authorship demographics. Descriptive frequencies were reported for all items.</p><p><strong>Results: </strong>Overall, 296 studies met the inclusion criteria to be considered relevant for global pediatric oncology. Of these, 259 (87.5%) were research articles. Of the research articles, 228 (88.0%) were observational and 117 (51.3%) were retrospective cohort analyses. Thirty-eight studies (12.8%) had a global focus or were unrelated to a geographic context, 54 (18.2%) were regional, and 204 (68.9%) were specific to a single country. Females represented 163 (55.8%) of first authors, 138 (46.6%) of senior authors, and 159 (53.7%) of corresponding authors. Furthermore, 121 (41.4%) first authors, 163 (55.1%) last authors, and 142 (48.0%) senior authors were from high-income countries (HICs). The United States (n = 81) and India (n = 40) had the most corresponding authors. Thirty-six (17.6%) articles had research conducted in low- and middle-income countries (LMICs), and the first, senior, and corresponding authors were from HICs.</p><p><strong>Conclusion: </strong>Our analysis shows that researchers from LMICs are under-represented as authors of global pediatric oncology publications. Further studies are needed to evaluate the factors that contribute to inequalities in global pediatric oncology research.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400320"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}